Logo

Ascletis Entered into an Exclusive WW License Agreement with Suzhou Alphamab for ASC22 (envafolimab) to Treat Hepatitis B and Other Viral Diseases

Share this

Ascletis Entered into an Exclusive WW License Agreement with Suzhou Alphamab for ASC22 (envafolimab) to Treat Hepatitis B and Other Viral Diseases

Shots:

  • Suzhou Alphamab to receive up front & will be eligible to receive development, regulatory & commercial milestones along with royalties & will manufacture ASC22 for clinical trials & commercialization of viral indications
  • Ascletis holds an exclusive & global license to develop & commercialize ASC22 for all viral diseases including Hepatitis B outside Greater China
  • ASC22 is currently being evaluated in the P-IIb trial in China. Additionally, preliminary P-IIb data showed an HBsAg reduction in ASC22 (1mg/kg, q2w) plus nucleos(t)ide analogs group with greater HBsAg reduction in patients with HBsAg = 500 IU/mL at baseline while no HBsAg reduction for PBO plus nucleos(t)ide analogs group

 Ref: Ascletis | Image: Ascletis

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions